Physician attitudes toward patient choice between the use of biologics and biosimilars vary widely across global markets, revealing deep-rooted cultural and systemic differences. While nearly half of (49%) physicians support patient involvement in treatment decisions, enthusiasm ranges from strong backing in China to notable skepticism in Germany and France—underscoring the growing but uneven shift toward […]